Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Septic Shock Patients With Microcirculatory Dysfunction
NCT07488689Phase 3Not yet recruiting
- Sponsor
- Strasbourg University Hospital
- Start
- Jul 2026
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin in septic shock, sponsored by Strasbourg University Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT07488689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07488689.